CoChat

Staging of Alzheimer's disease: past, present, and future perspectives

Therriault, Joseph, Zimmer, Eduardo R., Benedet, Andrea L., Pascoal, Tharick A., Gauthier, Serge, Rosa-Neto, Pedro · 2022 · Trends in Molecular Medicine
Cited by 113

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmed.2022.05.008

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 81

  1. Gonnella, 1984, Staging of disease. A case-mix measurement, JAMA, 251, 637, 10.1001/jama.1984.03340290051021 · DOI · Paper page
  2. Markson, 1991, Clinical outcomes management and disease staging, Eval. Health Prof., 14, 201, 10.1177/016327879101400205 · DOI
  3. Amin, 2017, The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more 'personalized' approach to cancer staging, CA Cancer J. Clin., 67, 93
  4. Villemagne, 2013, Amyloid-β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study, Lancet Neurol., 12, 357, 10.1016/S1474-4422(13)70044-9 · DOI · Paper page
  5. McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  6. Reisberg, 1982, The global deterioration scale for assessment of primary degenerative dementia, Am. J. Psychiatry, 139, 1136, 10.1176/ajp.139.9.1136 · DOI · Paper page
  7. van Harten, 2018, Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging, Neurology, 91, e300, 10.1212/WNL.0000000000005863 · DOI · Paper page
  8. Kryscio, 2014, Self-reported memory complaints: implications from a longitudinal cohort with autopsies, Neurology, 83, 1359, 10.1212/WNL.0000000000000856 · DOI · Paper page
  9. Del Tredici, 2020, To stage, or not to stage, Curr. Opin. Neurobiol., 61, 10, 10.1016/j.conb.2019.11.008 · DOI
  10. Braak, 1995, Staging of Alzheimer’s disease-related neurofibrillary changes, Neurobiol. Aging, 16, 271, 10.1016/0197-4580(95)00021-6 · DOI · Paper page
  11. Mirra, 1991, The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
  12. Abner, 2017, Outcomes after diagnosis of mild cognitive impairment in a large autopsy series, Ann. Neurol., 81, 549, 10.1002/ana.24903 · DOI
  13. Schneider, 2009, The neuropathology of probable Alzheimer disease and mild cognitive impairment, Ann. Neurol., 66, 200, 10.1002/ana.21706 · DOI · Paper page
  14. Sperling, 2014, The A4 study: stopping AD before symptoms begin?, Sci. Transl. Med., 6, 10.1126/scitranslmed.3007941 · DOI · Paper page
  15. Jack, 2019, Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia, JAMA, 321, 2316, 10.1001/jama.2019.7437 · DOI · Paper page
  16. Johnson, 2013, Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association, Alzheimers Dement., 54, 476
  17. Rabinovici, 2019, Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia, JAMA, 321, 1286, 10.1001/jama.2019.2000 · DOI · Paper page
  18. Therriault, 2021, Determining amyloid-β positivity using 18F-AZD4694 PET imaging, J. Nucl. Med., 62, 247, 10.2967/jnumed.120.245209 · DOI
  19. Altmann, 2015, Regional brain hypometabolism is unrelated to regional amyloid plaque burden, Brain, 138, 3734, 10.1093/brain/awv278 · DOI
  20. Sperling, 2020, Association of factors with elevated amyloid burden in clinically normal older individuals, JAMA Neurol., 77, 735, 10.1001/jamaneurol.2020.0387 · DOI · Paper page
  21. Jansen, 2015, Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis, JAMA, 313, 1924, 10.1001/jama.2015.4668 · DOI · Paper page
  22. Chiotis, 2018, Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia, Mol. Psychiatry, 23, 1666, 10.1038/mp.2017.108 · DOI
  23. Xia, 2017, Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease, JAMA Neurol., 74, 427, 10.1001/jamaneurol.2016.5755 · DOI · Paper page
  24. Therriault, 2021, Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia, Ann. Clin. Transl. Neurol., 8, 2083, 10.1002/acn3.51457 · DOI
  25. Pascoal, 2020, 18F-MK-6240 PET for early and late detection of neurofibrillary tangles, Brain, 143, 2818, 10.1093/brain/awaa180 · DOI · Paper page
  26. Therriault, 2020, Topographical distribution of amyloid-β, tau and atrophy in behavioral / dysexecutive AD patients, Neurology, 96, e81
  27. Scheltens, 2021, Alzheimer’s disease, Lancet, 397, 1577, 10.1016/S0140-6736(20)32205-4 · DOI · Paper page
  28. Fantoni, 2020, The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging, J. Nucl. Med., 61, 166, 10.2967/jnumed.119.235879 · DOI
  29. Pascoal, 2020, Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment, Alzheimers Dement., 12
  30. Collij, 2020, Multitracer model for staging cortical amyloid deposition using PET imaging, Neurology, 95, e1538, 10.1212/WNL.0000000000010256 · DOI · Paper page
  31. Lowe, 2018, Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia, Brain, 141, 271, 10.1093/brain/awx320 · DOI · Paper page
  32. Therriault, 2022, Biomarker modeling of Alzheimer’s disease using PET-based Braak staging, Nat. Aging., 10.1038/s43587-022-00204-0 · DOI · Paper page
  33. Franzmeier, 2020, Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease, Sci. Adv., 6, 10.1126/sciadv.abd1327 · DOI · Paper page
  34. Jacobs, 2018, Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals, Nat. Neurosci., 21, 424, 10.1038/s41593-018-0070-z · DOI · Paper page
  35. Pascoal, 2021, Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages, Brain, 144, 3517, 10.1093/brain/awab248 · DOI
  36. Vogel, 2020, Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease, Nat. Commun., 11, 2612, 10.1038/s41467-020-15701-2 · DOI · Paper page
  37. Vogel, 2022, Subtypes of Alzheimer’s disease: questions, controversy, and meaning, Trends Neurosci., 45, 342, 10.1016/j.tins.2022.02.001 · DOI
  38. Ossenkoppele, 2021, Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers, EMBO Mol. Med., 13, 10.15252/emmm.202114398 · DOI
  39. Barthélemy, 2020, A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease, Nat. Med., 26, 398, 10.1038/s41591-020-0781-z · DOI · Paper page
  40. Lantero-Rodriguez, 2021, P-tau235: a novel biomarker for staging preclinical Alzheimer’s disease, EMBO Mol. Med., 13, 10.15252/emmm.202115098 · DOI · Paper page
  41. Leuzy, 2021, Comparing the clinical utility and diagnostic performance of CSF p-Tau181, p-Tau217, and p-Tau231 assays, Neurology, 97, e1681, 10.1212/WNL.0000000000012727 · DOI · Paper page
  42. Ashton, 2021, Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology, Acta Neuropathol., 141, 709, 10.1007/s00401-021-02275-6 · DOI · Paper page
  43. Gauthier, 2020, Impact of p-tau181 and p-tau217 levels on enrolment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs, Expert. Rev. Neurother., 20, 1211, 10.1080/14737175.2020.1841637 · DOI
  44. Ashton, 2020, An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders, Nat. Rev. Neurol., 16, 265, 10.1038/s41582-020-0348-0 · DOI · Paper page
  45. Petersen, 2022, Are plasma markers for Alzheimer’s disease ready for clinical use? Nat, Aging, 2, 94
  46. Hansson, 2021, Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease, Ann. Clin. Transl. Neurol., 8, 259, 10.1002/acn3.51253 · DOI
  47. Ossenkoppele, 2018, Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders, JAMA, 320, 1151, 10.1001/jama.2018.12917 · DOI · Paper page
  48. Haeberlein, 2022, Two randomized Phase 3 studies of aducanumab in early Alzheimer’s disease, J. Prev. Alzheimer’s Dis., 9, 197, 10.14283/jpad.2022.30 · DOI · Paper page
  49. Hampel, 2021, Developing the ATX(N) classification for use across the Alzheimer disease continuum, Nat. Rev. Neurol., 17, 580, 10.1038/s41582-021-00520-w · DOI · Paper page
  50. Fan, 2017, An early and late peak in microglial activation in Alzheimer’s disease trajectory, Brain, 140, 792
  51. Souza, 2019, The astrocyte biochemistry, Semin. Cell Dev. Biol., 95, 142, 10.1016/j.semcdb.2019.04.002 · DOI
  52. Carter, 2019, Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease, Eur. J. Nucl. Med. Mol. Imaging, 46, 348, 10.1007/s00259-018-4217-7 · DOI
  53. Vilaplana, 2020, Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease, Neurology, 94, e2026, 10.1212/WNL.0000000000009405 · DOI
  54. Harada, 2021, 18F-SMBT-1: a selective and reversible PET tracer for monoamine oxidase-b imaging, J. Nucl. Med., 62, 253, 10.2967/jnumed.120.244400 · DOI
  55. Tyacke, 2018, Evaluation of 11C-BU99008, a positron emission tomography ligand for theimidazoline 2 binding site in human brain, J. Nucl. Med., 10, 1597, 10.2967/jnumed.118.208009 · DOI
  56. Calsolaro, 2021, Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load, Mol. Psychiatry, 26, 5848, 10.1038/s41380-021-01193-z · DOI
  57. Kumar, 2021, Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain, Mol. Psychiatry, 26, 5833, 10.1038/s41380-021-01101-5 · DOI · Paper page
  58. van der Weijden, 2021, Myelin quantification with MRI: a systematic review of accuracy and reproducibility, Neuroimage, 226, 10.1016/j.neuroimage.2020.117561 · DOI
  59. Power, 2018, Combined neuropathological pathways account for age-related risk of dementia, Ann. Neurol., 84, 10, 10.1002/ana.25246 · DOI · Paper page
  60. Eusebi, 2017, Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis, Mov. Disord., 32, 1389, 10.1002/mds.27110 · DOI · Paper page
  61. Zhou, 2015, The diagnostic and differential diagnosis utility of cerebrospinal fluid α-synuclein levels in Parkinson’s disease: a meta-analysis, Parkinsons. Dis., 2015
  62. Fayyad, 2019, Parkinson’s disease biomarkers based on α-synuclein, J. Neurochem., 150, 626, 10.1111/jnc.14809 · DOI
  63. Shi, 2010, Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease, Neurosci. Lett., 480, 78, 10.1016/j.neulet.2010.06.009 · DOI · Paper page
  64. Chang, 2016, Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer’s disease, Neurochem. Int., 97, 1, 10.1016/j.neuint.2016.04.012 · DOI
  65. Barbour, 2008, Red blood cells are the major source of alpha-synuclein in blood, Neurodegener. Dis., 5, 55, 10.1159/000112832 · DOI · Paper page
  66. Cairns, 2007, TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions, Am. J. Pathol., 171, 227, 10.2353/ajpath.2007.070182 · DOI · Paper page
  67. Chen-Plotkin, 2010, TAR DNA-binding protein 43 in neurodegenerative disease, Nat. Rev. Neurol., 6, 211, 10.1038/nrneurol.2010.18 · DOI · Paper page
  68. Josephs, 2008, Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype, Neurology, 70, 1850, 10.1212/01.wnl.0000304041.09418.b1 · DOI · Paper page
  69. Josephs, 2014, TDP-43 is a key player in the clinical features associated with Alzheimer’s disease, Acta Neuropathol., 127, 811, 10.1007/s00401-014-1269-z · DOI · Paper page
  70. Wilson, 2013, TDP-43 pathology, cognitive decline, and dementia in old age, JAMA Neurol., 70, 1418, 10.1001/jamaneurol.2013.3961 · DOI · Paper page
  71. Foulds, 2008, TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration, Acta Neuropathol., 116, 141, 10.1007/s00401-008-0389-8 · DOI · Paper page
  72. Williams, 2017, Blood-based oligomeric and other protein variant biomarkers to facilitate pre-symptomatic diagnosis and staging of Alzheimer’s disease, J. Alzheimers Dis., 58, 23, 10.3233/JAD-161116 · DOI
  73. Goossens, 2015, TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies, Acta Neuropathol. Commun., 3, 15, 10.1186/s40478-015-0195-1 · DOI
  74. Salloway, 2021, A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease, Nat. Med., 27, 1187, 10.1038/s41591-021-01369-8 · DOI · Paper page
  75. Tian Hui Kwan, 2020, Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials, Dement. Geriatr. Cogn. Disord., 3, 334, 10.1159/000511506 · DOI
  76. Levey, 2021, Progress with treatments for Alzheimer’s disease, N. Engl. J. Med., 384, 1762, 10.1056/NEJMe2103722 · DOI
  77. Morris, 2019, Assessment of racial disparities in biomarkers for Alzheimer disease, JAMA Neurol., 76, 264, 10.1001/jamaneurol.2018.4249 · DOI · Paper page
  78. Gauthier, 2006, Mild cognitive impairment, Lancet, 367, 1262, 10.1016/S0140-6736(06)68542-5 · DOI · Paper page
  79. Liang, 2021, Mortality rates in Alzheimer’s disease and non-Alzheimer’s dementias: a systematic review and meta-analysis, Lancet Heal. Longev., 2, e479, 10.1016/S2666-7568(21)00140-9 · DOI · Paper page
  80. Morris, 1993, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology, 43, 2412, 10.1212/WNL.43.11.2412-a · DOI · Paper page
  81. McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement., 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page

Cited by

See all 113

Metadata

Authors
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P.
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2022-09
Volume
28
Issue
9
Pages
726-741
ISSN
1471-4914
Cited by
113
References
75
Language
en
Funders
Canadian Institutes of Health Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.